郭翼，同济大学妇产科学博士，美国宾夕法尼亚大学Perelman医学院联合培养博士，主要研究方向为妇科肿瘤的发病机制及靶向治疗的研究。目前发表的SCI收录论文10余篇，最高影响因子为7.19分，发表国内外大会论文4篇，作为负责人主持国家自然基金1项及院级课题1项，获得上海市青年医师培养资助计划、同济大学青年优秀人才培养资助计划、上海市同济医院后备人才培养计划（甘泉新星）等人才项目。为上海市医学会妇产科分会青年委员。2016年获得同济医院“金教鞭”全英文讲课比赛规培组一等奖，2017年获得同济医院“金教鞭”全英文讲课比赛一等奖。

Yi Guo, PhD, MD, Attending, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji University School of Medicine. Yi Guo pursued her doctor’s degree by joint-supervision of Tongji University and University of Pennsylvania. She is now the member of Youth Commission of Shanghai Medical Association (OBG division). Her research focused on the mechanism of gynecological malignant and its targeted therapy. She has more than 10 publications with the highest impact factor of 7.19. She is sponsored by National Nature Science Foundation of China and Youth Scientists Grants of Tongji hospital. She is also included in Young Excellent Doctor Fostering Program of Shanghai, Young Excellent Talents fostering Program of Tongji University, New-Arising Promising Doctors Program of Tongji Hospital. She is the winner in contests of Medical Teaching in English for two years in a row (2016 and 2017). She now participates in education and instruction for interns.

1. 主持或参加科研项目（课题）及人才计划项目情况：

(5 grants as PI, 2 grants as participant )

1) 2016年同济医院青年项目（TJ1611），主持，课题名称为“TEM1促进子宫肉瘤侵袭、转移的机制研究”，2016-2018；

2) 2017年上海市青年医师资助培养计划”，主持，2017-2020；

3) 2017年同济大学青年优秀人才培养资助计划，主持，2017-2020;

4) 2018年国家自然基金青年项目（81802583），主持，TEM1介导的MMPs/integrin通路促进子宫肉瘤侵袭转移的机制研究，2019.01-2021. 12；

5) 2018年同济医院后备人才培养资助计划“甘泉新星”，主持，2019-2022；

6) 国家十二五科技支撑计划项目，No. 2012BAI17B05，盆底功能修复软组织重建材料的研发，2012.01至2015.12，744.0万，已结题，参加。

7) 上海市科委课题，No.124119a3800，检测高危HPV DNA的整合状态预测宫颈癌变，2012.12.1-2015.12.1, 30万，已结题，参加。

2. 代表性研究成果和学术奖励情况

一、期刊论文

第一及共同第一作者. (First and co-first author articles )

1) Y Guo#, J Hu#, Y Wang, X Peng, J Min, J Wang, E Matthaiou, Y Cheng, K Sun, X Tong, Y. Fan, P J Zhang, L E Kandalaft, M Irving f, G Coukos, C Li. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma. European J Cancer, Volume 90, February 2018, Pages 111–121.

2) Yi Guo#, Kewei Chen#, Ying Zhang#, et al. TEM1 knockdown inhibits proliferation and metastasis in MES-SA uterine sarcoma. Int J Clin Exp Med. 2017;10(9):13133-13142.

3) Guo Y#, Hu J, Zhu L, Sun J, Xie L, Kong F, Han L, Li F*. Physical Status and Variant Analysis of Human Papillomavirus 16 in Women from Shanghai. Gynecologic and Obstetric Investigation. 2016;81(1):61-70. doi: 10.1159/000381775.

4) Chen, Yao#; Xu, Mengjiao#; Guo, Yi#; Tu, Keyao; Wu, Weimin; Wang, Jianjun; Tong, Xiaowen; Wu, Wenjuan; Qi*, Lifeng*; Shi, Donglu Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle. Nanotechnology. 2016.9. Nanotechnology. 2017Jan 13;28(2):025101.

5) Deng J^#, Guo Y^#, Jiang Z, Yang M, Li H, Wang J*. Enhancement of Ovarian Cancer Chemotherapy by Delivery of Multidrug-Resistance Gene Small Interfering RNA Using Tumor Targeting Salmonella. The Journal of Obstetrics and Gynaecology Research. J Obstet Gynaecol Res. 2015 Apr;41(4):615-22. doi: 10.1111/jog.12598.

非第一非通讯作者文章 (Co-author articles)

1) Chunsheng li, Junying Wang, Effthymia Matthaiou, Yi Guo, et al. Immuno-imaging and therapy in ovarian cancer and sarcoma with de novo single chain fv-fv fusion protein targeting TEM1/CD248. J immunother Cancer, 2014; 2(Suppl 3):P219.

2) Zhao JW, Fang F, Guo Y, et al. HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability. J Exp Clin Cancer Res. 2016 Nov 25;35(1):180

3) Li F#, Guo Y, Han L, Duan Y, Fang F, Niu S, Ba Q, Zhu H, Kong F, Lin C*, Wen X*. In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus. Oncol Lett. 2012 Dec;4(6):1254-1258.

4) Li #F, Ba Qiujie#, Niu Sumei, Guo Yi, Shi Donglu*. In-situ forming biodegradable glycol chitosan-based hydrogels: Synthesis, characterization, and chondrocyte culture. Materials Science and Engineering C-biomimetic and Supramolecular Systems. 2012.05.021, 2017 - 2025 10.1016/j.msec.

5) Li F#, Niu S#, Sun J, Zhu H, Ba Q, Guo Y, Shi D*. Efficient In Vitro TRAIL-Gene Delivery in Drug-Resistant A2780/DDP Ovarian Cancer Cell Line via Magnetofection. JOURNAL OF NANOMATERIALS. DOI: 10.1155/2011/484589.

二、 会议论文 (Conference articles)

1) Yi Guo, Junying Wang, Jia Hu, Xiaohui Peng, Chunsheng Li. Development of Immunotoxin Targeting TEM1/CD248 for sarcoma. Translational Research Cancer Centers Consortium. Feb18-20, 2015.

2) Yi Guo, Jiaqi Deng, Jianjun Wang. Enhancement of Ovarian Cancer Chemotherapy by Delivery of Multidrug-Resistance Gene Small Interfering RNA Using Tumor Targeting Salmonella. Dec 7-9, 2015, Busan, Korea.

3) Chunsheng Li, Junying Wang, Efthymia Iliana Matthaiou, Yi Guo, et al. Immuno-imaging and -therapy in Ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targetingTEM1/CD248.Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3): P219. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor,MD, USA. 6-9 November 2014.